

See “Trough level of infliximab is useful for assessing mucosal healing in Crohn’s disease: a prospective cohort study” on page 223.

Supplementary Table 3. Comparison of Characteristics of MH and nMH Groups in Small Intestine and Colon in Study 2

Characteristics	MH	nMH	P-value
Small intestine			
No. of patients	10	21	
Age at diagnosis (yr)	18.6 (15–32)	29.9 (11–48)	0.0898
Female/male	1/9	2/19	NS
Duration of IFX treatment (yr)	2.5 (1–5)	2.8 (1–5)	0.5882
No. of IFX 10 mg/kg	3	5	NS
The median length of ileum inserted (cm)	68.0±57.6 (7–150)	45.1±48.4 (9–150)	0.2811
Total CDAI score	103.5±57.4 (42–285)	134.0±77.9 (25–299)	0.2907
CRP (mg/dL)	1.0±2.4 (0.1–7.8)	0.8±1.5 (0.0–2.4)	0.3102
No. of current immunosuppressant	5	6	0.4232
Colon			
No. of patients	13	8	
Age at diagnosis (yr)	22.1 (11–34)	21.8 (16–26)	0.9420
Female/male	1/12	1/7	NS
Duration of IFX treatment (yr)	2.3 (1–5)	2.4 (1–5)	0.6556
No. of IFX 10 mg/kg	2	3	0.3254
Total CDAI score	128.6±85.9 (31–299)	126.5±75.4 (25–207)	0.8280
CRP (mg/dL)	0.5±0.6 (0.0–2.3)	0.9±1.0 (0.1–3.3)	0.0597
No. of current immunosuppressant	5	4	0.6731

Values are presented mean (range) or mean±SD (range).

MH, mucosal healing; nMH, non-MH; IFX, infliximab.